Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist ...Middle East

SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156,...

Hence then, the article about yunovia announces ind approval by the mfds to initiate phase 1 mad study for the small molecule glp 1 agonist was published today ( Wednesday 28/08/2024 - 05:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist )

Also on site :

• TIER IV unveils AI-based Level 4 autonomous driving, accelerating global platform expansion across Japan, U.S. and Europe
• Armed police close Lewes Road
• Fire erupts at Dubai airport following drone attack